Home Newsfeeds Baird Maintains Outperform on PerkinElmer, Raises Price Target to $202

Baird Maintains Outperform on PerkinElmer, Raises Price Target to $202

Baird analyst Catherine Schulte maintains PerkinElmer (NYSE:PKI) with a Outperform and raises the price target from $198 to $202.

byBenzinga Newsdesk

August 2, 2022

1 minute read

Baird analyst Catherine Schulte maintains PerkinElmer (NYSE:PKI) with a Outperform and raises the price target from $198 to $202.

Pure Storage Issues Weak Forecast, Joins Frontline, Weibo And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

By Lisa Levin

November 30, 7:08 AM

U.S. stock futures traded higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday.

CDT

Goldman Sachs Maintains Buy on YETI Holdings, Lowers Price Target to $55

By Benzinga Newsdesk

July 21, 7:21 AM

Goldman Sachs analyst Brooke Roach maintains YETI Holdings (NYSE:YETI) with a Buy and lowers the price target from $65 to $55.

YETI

Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?

By Vandana Singh

February 15, 4:29 PM

Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.

ALNY

Snap Q2 Earnings Highlights: Stock Tanks On No Q3 Guidance, Revenue And EPS Miss

By Chris Katje

July 21, 4:37 PM

Camera company and Snapchat parent company Snap Inc (NYSE: SNAP) is falling after-hours Thursday after reporting second-quarter financial results. Here are the key highlights.

SNAP

Baird Maintains Outperform on PerkinElmer, Raises Price Target to $202

Related Posts

Pure Storage Issues Weak Forecast, Joins Frontline, Weibo And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

Goldman Sachs Maintains Buy on YETI Holdings, Lowers Price Target to $55

Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?

Snap Q2 Earnings Highlights: Stock Tanks On No Q3 Guidance, Revenue And EPS Miss